Plasma hsa‐mir‐19b is a potential LevoDopa therapy marker

Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs. LevoDopa replacement is the gold standard therapy for PD, as it ameliorates the motor symptoms. However, it does not affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Chis, Aimee Rodica, Moatar, Alexandra Ioana, Dijmarescu, Cristina, Rosca, Cecilia, Vorovenci, Ruxandra Julia, Krabbendam, Inge, Dolga, Amalia, Bejinar, Cristina, Marian, Catalin, Sirbu, Ioan Ovidiu, Simu, Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435426/
https://www.ncbi.nlm.nih.gov/pubmed/34328686
http://dx.doi.org/10.1111/jcmm.16827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435426/
https://www.ncbi.nlm.nih.gov/pubmed/34328686
http://dx.doi.org/10.1111/jcmm.16827

Ejemplares similares